Pasithea Therapeutics (KTTA) Cash from Operations (2021 - 2026)
Pasithea Therapeutics recorded quarterly Cash from Operations of 4787220.0 in Q1 2026, up 11.3% quarter-over-quarter from 5396822.0 in Q4 2025, and down 56.66% year-over-year from 11046324.32 in Q1 2025.
Pasithea Therapeutics' Cash from Operations history runs 6 years deep, the most recent figure standing at 4787220.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 56.66% year-over-year to 4787220.0; the TTM figure through Mar 2026 stood at 16942953.0 (down 33.85% YoY), while the FY2025 annual figure was 15211490.0, down 9.25% from the prior year.
- Cash from Operations came in at 4787220.0 for Q1 2026 at Pasithea Therapeutics, up from 5396822.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1935427.0 in Q2 2022 to a low of 5396822.0 in Q4 2025.
- A 5-year average of 3448873.41 and a median of 3202278.0 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations tumbled 742.68% in 2022 and rose 29.94% in 2023, its largest moves.
- Pasithea Therapeutics' Cash from Operations stood at 3185388.0 in 2022, then dropped by 3.42% to 3294344.0 in 2023, then increased by 25.84% to 2443036.0 in 2024, then plunged by 120.91% to 5396822.0 in 2025, then grew by 11.3% to 4787220.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 4787220.0, 5396822.0, and 2890025.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | -4.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.79 Mn |
| Mar 31, 2026 | -4.79 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Sep 30, 2025 | -2.89 Mn |
| Jun 30, 2025 | -3.87 Mn |
| Jun 30, 2025 | -3.87 Mn |
| Mar 31, 2025 | -3.06 Mn |
| Mar 31, 2025 | -3.06 Mn |
| Dec 31, 2024 | -2.44 Mn |
| Dec 31, 2024 | -2.44 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Jun 30, 2024 | -4.04 Mn |
| Jun 30, 2024 | -4.04 Mn |
| Mar 31, 2024 | -4.32 Mn |
| Mar 31, 2024 | -4.32 Mn |
| Dec 31, 2023 | -3.29 Mn |
| Dec 31, 2023 | -3.29 Mn |
| Sep 30, 2023 | -3.24 Mn |
| Sep 30, 2023 | -3.24 Mn |
| Jun 30, 2023 | -3.08 Mn |
| Jun 30, 2023 | -3.08 Mn |
| Mar 31, 2023 | -3.20 Mn |
| Mar 31, 2023 | -3.20 Mn |
| Dec 31, 2022 | -3.19 Mn |
| Dec 31, 2022 | -3.19 Mn |
| Sep 30, 2022 | -4.62 Mn |
| Sep 30, 2022 | -4.62 Mn |
| Jun 30, 2022 | -1.94 Mn |
| Jun 30, 2022 | -1.94 Mn |
| Mar 31, 2022 | -2.15 Mn |
| Mar 31, 2022 | -2.15 Mn |
| Dec 31, 2021 | -1.74 Mn |
| Dec 31, 2021 | -1.74 Mn |
| Sep 30, 2021 | -548,442.00 |
| Sep 30, 2021 | -548,442.00 |
| Jun 30, 2021 | -499,438.00 |
| Jun 30, 2021 | -499,438.00 |
| Mar 31, 2021 | -381,845.00 |
| Mar 31, 2021 | -381,845.00 |